Analysis of autophagosome formation in myelodysplastic syndrome

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K16582
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 49020:Human pathology-related
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: Onishi Iichiroh 東京医科歯科大学, 大学院医歯学総合研究科, 助教 (70750214)
• Project Period (FY): 2019-04-01 – 2021-03-31
• Keywords: 骨髄異形成症候群 / オートファゴソーム / LC3B / 予後解析

Outline of Final Research Achievements

This is the first study to examine the presence or absence of autophagy in neoplastic hematopoietic cells by immunohistochemistry in myelodysplastic syndrome (MDS). LC3B immunohistochemistry found that patients with autophagy had a significantly poorer prognosis, and LC3B immunostaining was used to stratify MDS patients, and in addition to conventional chemotherapy, autophagosome inhibitors were used. We have found that it may improve the prognosis of patients by using it. We would like to verify the usefulness of autophagosome inhibitors using cell lines.

Free Research Field

血液病理学

Academic Significance and Societal Importance of the Research Achievements

本研究では、LC3Bの免疫染色によりMDS患者の層別化が可能であることを示しており、今後MDS患者の治療方針等にも関係する可能性のあるものである。そのためには、さらに大規模な症例での検討、MDSの白血病化前の細胞株を用いた検討も、今後必要である。